Condition: Limited Stage Small Cell Lung Cancer · Sponsor: SCRI Development Innovations, LLC
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants. The main goals of this study are to: * Evaluate the efficacy of BMS-986489 vs durvalumab * Evaluate the safety profile of BMS-986489
This description comes directly from the study's public registry record.
Sarah Cannon Development Innovations, LLC · 1-844-710-6157 · SCRI.InnovationsMedical@scri.com
Always discuss trial participation with your own doctor first.
| Southern Cancer Center | Daphne, Alabama, United States | Recruiting |
| Sansum Clinic | Santa Barbara, California, United States | Recruiting |
| Florida Cancer Specialists - South | Fort Myers, Florida, United States | Recruiting |
| University of Miami - Sylvester Cancer Center | Miami, Florida, United States | Active Not Recruiting |
| Ocala Oncology Center | Ocala, Florida, United States | Recruiting |
| Florida Cancer Specialists - North | Orange City, Florida, United States | Recruiting |
| Cancer Care Centers of Brevard | Palm Bay, Florida, United States | Recruiting |
| Florida Cancer Specialists - East | West Palm Beach, Florida, United States | Recruiting |
| Piedmont Healthcare - Atlanta | Atlanta, Georgia, United States | Recruiting |
| Illinois Cancer Specialists | Arlington Heights, Illinois, United States | Recruiting |
| Illinois Cancer Care | Peoria, Illinois, United States | Recruiting |
| Indiana University Simon Cancer Center | Indianapolis, Indiana, United States | Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06773910